NewAmsterdam Pharma Company N.V. announced the appointment of Ian Somaiya as Chief Financial Officer (?CFO?). Mr. Somaiya is an established healthcare executive with extensive financial and operational expertise, including over two decades of experience on Wall Street as a prominent biotechnology research analyst. Mr. Somaiya joins NewAmsterdam Pharma with over twenty-five years?

experience in senior leadership roles in the biopharmaceutical industry. Mr. Somaiya most recently served as CFO and Chief Business Officer of Elucida Oncology and, before that, as CFO of TCR2 Therapeutics, where he guided the company through its initial public offering and two subsequent follow on offerings, as well as led the company?s finance, reporting, business head of biotechnology research at BMO Capital Markets. He also served as managing director and equity analyst at Nomura Securities, Piper Jaffray, and Thomas Weisel Partners.

He started his career on Wall Street as a research analyst at Morgan Stanley and Prudential Securities. Throughout his 20-year tenure on Wall Street, Mr.Somaiya was a highly esteemed industry equity analyst who conducted comprehensive research on more than 100 biotechnology companies across diverse therapeutic areas, technology platforms, and stages of development. He was recognized for several consecutive years as the ?Best on the Street?

by The Wall Street Journal for his research coverage in the biotech sector. Mr. Somaiya received a B.A. in Biology and Neuroscience from New York University.